This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Natural Hormone Replacement Pioneer Challenges Incomplete Testosterone Studies

DALLAS, Nov. 8, 2013 /PRNewswire/ -- BioTE Medical Founder Dr. Gary Donovitz today challenged recent reports that have been critical of testosterone replacement therapy.   Media coverage has reported that testosterone replacement therapy was over-prescribed by physicians, often unnecessary and in some cases dangerous for consumers.     

(Photo: http://photos.prnewswire.com/prnh/20131108/DA13647)

Dr. Donovitz, whose company BioTE Medical is a leading provider of natural hormone replacement therapy using subcutaneous pellets, was critical of what he called a general lack of depth in research. Donovitz said, "We see significant flaws in the information that's being presented to the public. Studies based solely on pharmaceutical products are being applied to all testosterone therapy.  As a result, credible research which is essential to a full understanding of testosterone therapy has not been considered."    

The Wall Street Journal on November 6, 2013 published an article that was critical of testosterone replacement therapy.  The publication cited a research study of veterans which claimed that testosterone therapy raised the risk of heart attack and stroke by about 30%.  Because the focus of the study was limited to pharmaceutical products, Dr. Donovitz said the research and its conclusions are flawed and incomplete.  Dr. Donovitz added, "The study referenced in the Wall Street Journal article is limited to the synthetic gels, patches and shots which are being heavily promoted on television and radio.  These pharmaceutical products use synthetic hormones and we've known about the dangers of synthetics for years.  However, to be accurate and complete, any study of testosterone therapy needs to also include data for natural hormone replacement. "

In addition to calling the Wall Street Journal research incomplete, Dr. Donovitz said that the study had other issues that impacted its integrity. According to Donovitz, many of the 23,173 veterans that were excluded from the study would have benefitted from proper testosterone optimization using natural hormone replacement.  Donovitz also expressed concern that the sample, which consisted of elderly men, was skewed because of a high incidence of conditions such as hypertension, diabetes and hyperlipidemia.  Another anomaly of the study, according to Donovitz, is the fact that of the 1223 skewed patients prescribed testosterone gels, patches and creams, only 20% filled one prescription.   Donovitz added, "The level of patient monitoring and care after the procedure was not sufficient.  60% of the patients administered testosterone had follow up laboratory assessments of their serum testosterone.  You cannot expect results without optimization and that requires laboratory assessment." 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs